File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Effect of lamivudine therapy on the serum covalently closed circular DNA of chronic hepatitis B infection

TitleEffect of lamivudine therapy on the serum covalently closed circular DNA of chronic hepatitis B infection
Authors
Issue Date2004
PublisherJohn Wiley & Sons, Inc.
Citation
The 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA., 29 October-2 November 2004. In Hepatology, 2004, v. 40 n. S4, p. 671A, abstract no. 1164 How to Cite?
AbstractBACKGROUND: In a recent study we demonstrated that serum covalently closed circular (ccc) hepatitis B virus (HBV) DNA is present in 93% of HBeAg-positive patients and that it correlates well with intrahepatic cccDNA (r=0.52, p=O.O04)(Wong DKH et al Hepatology 2004 in press). Serum cccDNA is good marker for intrahepatic cccDNA and has the advantage of easy monitoring. The effect of lamivudine on ccc DNA in HBV infection is unknown. AIM: To determine the effect of one-year lamivudine treatment on serum cccDNA level. PATIENTS AND METHODS: Total HBV DNA and cccDNA levels at baseline, week 24 and 52 were measured in 82 lamindine-treated patients, 17 of whom acted as controls when they received placebo in the first year. RESULTS: There was a significant reduction in the cccDNA levels from baseline (median 3.0 X lo6 copieslml) to week 24 (33,476 copies/ml) and week 52 (48,694 copieslml) (p < 0.001 for both) in lamivudine-treated patients. The median reduction in serum cccDNA level at week 24 and 52 were 2.21 and 2.12 logs respectively, which were significantly greater than those of patients taking placebo (0.31 log, p < 0.001; 0.2 log, p < 0.001 respectively). Fifteen patients (18.3%) developed YMDD mutations by week 52. The median logarithmic reduction of cccDNA at week 52 was significantly less in patients with YMDD mutations compared to patients without YMDD mutations (0.8 vs. 2.35 logs respectively, p < 0.001). Compared to patients without YMDD mutations at week 52, patients with YMDD mutations had a significantly lesser median logarithmic reduction of total HBV DNA and cccDNA levels at week 24 [total HBV DNA 4.44 vs. 3.65 respectively, p=0.02; cccDNA: 2.27 vs. 1.65 respectively, p=O.O16)]. CONCLUSIONS: One-year lamivudine treatment decreased the serum cccDNA level by 2 logs. The chance of emergence of YMDD mutations at week 52 was related to the magnitude of viral suppression at week 24.
Persistent Identifierhttp://hdl.handle.net/10722/101475
ISSN
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorYuen, RMFen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorSum, SMen_HK
dc.contributor.authorYuan, Hen_HK
dc.contributor.authorYuen, JCHen_HK
dc.contributor.authorChan, OOen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-25T19:51:10Z-
dc.date.available2010-09-25T19:51:10Z-
dc.date.issued2004en_HK
dc.identifier.citationThe 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA., 29 October-2 November 2004. In Hepatology, 2004, v. 40 n. S4, p. 671A, abstract no. 1164en_HK
dc.identifier.issn1527-3350-
dc.identifier.urihttp://hdl.handle.net/10722/101475-
dc.description.abstractBACKGROUND: In a recent study we demonstrated that serum covalently closed circular (ccc) hepatitis B virus (HBV) DNA is present in 93% of HBeAg-positive patients and that it correlates well with intrahepatic cccDNA (r=0.52, p=O.O04)(Wong DKH et al Hepatology 2004 in press). Serum cccDNA is good marker for intrahepatic cccDNA and has the advantage of easy monitoring. The effect of lamivudine on ccc DNA in HBV infection is unknown. AIM: To determine the effect of one-year lamivudine treatment on serum cccDNA level. PATIENTS AND METHODS: Total HBV DNA and cccDNA levels at baseline, week 24 and 52 were measured in 82 lamindine-treated patients, 17 of whom acted as controls when they received placebo in the first year. RESULTS: There was a significant reduction in the cccDNA levels from baseline (median 3.0 X lo6 copieslml) to week 24 (33,476 copies/ml) and week 52 (48,694 copieslml) (p < 0.001 for both) in lamivudine-treated patients. The median reduction in serum cccDNA level at week 24 and 52 were 2.21 and 2.12 logs respectively, which were significantly greater than those of patients taking placebo (0.31 log, p < 0.001; 0.2 log, p < 0.001 respectively). Fifteen patients (18.3%) developed YMDD mutations by week 52. The median logarithmic reduction of cccDNA at week 52 was significantly less in patients with YMDD mutations compared to patients without YMDD mutations (0.8 vs. 2.35 logs respectively, p < 0.001). Compared to patients without YMDD mutations at week 52, patients with YMDD mutations had a significantly lesser median logarithmic reduction of total HBV DNA and cccDNA levels at week 24 [total HBV DNA 4.44 vs. 3.65 respectively, p=0.02; cccDNA: 2.27 vs. 1.65 respectively, p=O.O16)]. CONCLUSIONS: One-year lamivudine treatment decreased the serum cccDNA level by 2 logs. The chance of emergence of YMDD mutations at week 52 was related to the magnitude of viral suppression at week 24.-
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc.-
dc.relation.ispartofHepatologyen_HK
dc.titleEffect of lamivudine therapy on the serum covalently closed circular DNA of chronic hepatitis B infectionen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailYuen, RMF: mfyuen@hkucc.hku.hken_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailSum, SM: siu_man_sum@hotmail.comen_HK
dc.identifier.emailYuen, JCH: jchyuen@HKUCC.hku.hken_HK
dc.identifier.emailChan, OO: aoochan@hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, RMF=rp00479en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/hep.1840400507-
dc.identifier.hkuros105365en_HK
dc.identifier.volume40en_HK
dc.identifier.issuesuppl. S4en_HK
dc.identifier.spage671A, abstract no. 1164en_HK
dc.identifier.epage671A, abstract no. 1164-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats